Orelli: BioSante melanoma deal could be better

Motley Fool's Brian Orelli weighed in on BioSante Pharmaceuticals' $100,000 upfront deal with the John P. Hussman Foundation for melanoma vaccine development, saying he considered the deal less than stellar. While the company could get up to $39 million in milestone payments, it didn't partner with a big name company, although there are several such players in the melanoma arena. One probable reason? Immunotherapies are still deemed too risky. Article

Suggested Articles

The scientific community has again been caught off guard and industry officials are talking about implementing better preventive measures.

Sanofi didn't hesitate to enter Zika vaccine R&D, and despite the associated scandal, the company is again jumping into emerging disease vaccine R…

NIH and Moderna will need a coronavirus vaccine manufacturer, and and no major pharmaceutical company has stepped up.